Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.

Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A.

EBioMedicine. 2017 Aug;22:164-172. doi: 10.1016/j.ebiom.2017.07.013. Epub 2017 Jul 15.


Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.

Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A.

PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016. Review.


Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.

Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A.

Lancet Infect Dis. 2014 Feb;14(2):119-29. doi: 10.1016/S1473-3099(13)70241-X. Epub 2013 Nov 28.


Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Gill CJ, Ram S, Welsch JA, Detora L, Anemona A.

Vaccine. 2011 Dec 9;30(1):29-34. doi: 10.1016/j.vaccine.2011.10.068. Epub 2011 Nov 7.


Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.

van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A.

PLoS One. 2011;6(9):e25398. doi: 10.1371/journal.pone.0025398. Epub 2011 Sep 30.


Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.

Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM.

Vaccine. 2010 Apr 19;28(18):3171-9. doi: 10.1016/j.vaccine.2010.02.045. Epub 2010 Feb 26.


Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.

Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F.

Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22.


Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.


A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM.

Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.


Sample size for equivalence trials: a case study from a vaccine lot consistency trial.

Ganju J, Izu A, Anemona A.

Stat Med. 2008 Aug 30;27(19):3743-54. doi: 10.1002/sim.3273.


Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. Erratum in: JAMA. 2011 Mar 16;305(11):1096.


Low specificity of the Murex fourth-generation HIV enzyme immunoassay in Tanzanian adolescents.

Everett DB, Weiss HA, Changalucha J, Anemona A, Chirwa T, Ross DA, Watson-Jones D, Parry JV, Hayes R, Mabey DC.

Trop Med Int Health. 2007 Nov;12(11):1323-6. Epub 2007 Oct 22.


Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial.

Ross DA, Changalucha J, Obasi AI, Todd J, Plummer ML, Cleophas-Mazige B, Anemona A, Everett D, Weiss HA, Mabey DC, Grosskurth H, Hayes RJ.

AIDS. 2007 Sep 12;21(14):1943-55.


Acceptability of azithromycin for the control of trachoma in Northern Tanzania.

Desmond N, Solomon AW, Massae PA, Lema N, Anemona A, Foster A, Mabey DC.

Trans R Soc Trop Med Hyg. 2005 Sep;99(9):656-63.


"A bit more truthful": the validity of adolescent sexual behaviour data collected in rural northern Tanzania using five methods.

Plummer ML, Ross DA, Wight D, Changalucha J, Mshana G, Wamoyi J, Todd J, Anemona A, Mosha FF, Obasi AI, Hayes RJ.

Sex Transm Infect. 2004 Dec;80 Suppl 2:ii49-56.


Asking semi-literate adolescents about sexual behaviour: the validity of assisted self-completion questionnaire (ASCQ) data in rural Tanzania.

Plummer ML, Wight D, Ross DA, Balira R, Anemona A, Todd J, Salamba Z, Obasi AI, Grosskurth H, Changalunga J, Hayes RJ.

Trop Med Int Health. 2004 Jun;9(6):737-54.


Variations of HIV and STI prevalences within communities neighbouring new goldmines in Tanzania: importance for intervention design.

Clift S, Anemona A, Watson-Jones D, Kanga Z, Ndeki L, Changalucha J, Gavyole A, Ross DA.

Sex Transm Infect. 2003 Aug;79(4):307-12.


Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine.

Kanra G, Viviani S, Yurdakök K, Ozmert E, Anemona A, Yalçin S, Demiralp O, Bilgili N, Kara A, Cengiz AB, Mutlu B, Baldini A, Marchetti E, Podda A.

Pediatr Int. 2003 Jun;45(3):314-8.


Myopia in secondary school students in Mwanza City, Tanzania: the need for a national screening programme.

Wedner SH, Ross DA, Todd J, Anemona A, Balira R, Foster A.

Br J Ophthalmol. 2002 Nov;86(11):1200-6.


Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group.

Pediatrics. 2001 Nov;108(5):E81.


Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

Tozzi AE, Anemona A, Stefanelli P, Salmaso S, Ciofi degli Atti ML, Mastrantonio P, Giammanco A; Progetto Pertosse Study Group.

Pediatrics. 2001 Feb;107(2):E25.


Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age.

Ciofi degli Atti M, Anemona A, Tozzi AE, Stefanelli P, Giammanco A, Salmaso S.

Vaccine. 1999 Apr 9;17(15-16):2030-5.


Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group.

Salmaso S, Anemona A, Mastrantonio P, Stefanelli P, Tozzi AE, Ciofi degli Atti ML.

Dev Biol Stand. 1998;95:189-94. No abstract available.


Repeat whole cell vaccinations should be avoided after hypotonic-hyporesponsive episodes.

Tozzi AE, Ciofi degli Atti ML, Salmaso S, Anemona A.

BMJ. 1998 Aug 29;317(7158):604. No abstract available.


Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group.

Salmaso S, Mastrantonio P, Wassilak SG, Giuliano M, Anemona A, Giammanco A, Tozzi AE, Ciofi degli Atti ML, Greco D.

Vaccine. 1998 Aug;16(13):1270-5. Erratum in: Vaccine 1999 Feb 5;17(5):I-II.


Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines.

Tozzi AE, Ciofi degli Atti ML, Wassilak SG, Salmaso S, Panei P, Anemona A, Luzi S, Greco D.

Vaccine. 1998 Jan-Feb;16(2-3):320-2.


Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates.

Mastrantonio P, Stefanelli P, Giuliano M, Herrera Rojas Y, Ciofi degli Atti M, Anemona A, Tozzi AE.

J Clin Microbiol. 1998 Apr;36(4):999-1002.


Differences by antigen in seroconversion: sensitivity, specificity and bias in the serological confirmation of pertussis.

Wassilak SG, Anemona A, Giuliano M, Giammanco A.

Dev Biol Stand. 1997;89:221-8. Review.


Case definitions.

Salmaso S, Moiraghi A, Barale A, Ferraro P, Dal Lago P, Coppola N, Materassi P, Barbuti S, Lo Palco P, Anemona A.

Dev Biol Stand. 1997;89:135-42.


Incidence of invasive Haemophilus influenzae type b disease in Italian children.

Tozzi AE, Salmaso S, Ciofi degli Atti ML, Panei P, Anemona A, Scuderi G, Wassilak SG.

Eur J Epidemiol. 1997 Jan;13(1):73-7.


Predicting the accrual rate in a vaccine clinical trial: an a posteriori evaluation of the feasibility study.

Tozzi AE, Cofi Degli Atti ML, Panei P, Anemona A, Binkin N, Salmaso S, Luzi S, Greco D.

Rev Epidemiol Sante Publique. 1996 Oct;44(5):387-93.


A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, Klein DL, Wassilak SG.

N Engl J Med. 1996 Feb 8;334(6):341-8.


[Epidemiology of invasive infections with Haemophilus influenzae type b in the world and in Italy].

Tozzi AE, Panei P, Ciofi degli Atti M, Anemona A, Scuderi G, Salmaso S.

Ann Ig. 1995 Jul-Aug;7(4):235-41. Italian.


Supplemental Content

Loading ...
Support Center